Ensign Peak Advisors
AVXL icon

Ensign Peak Advisors’s Anavex Life Sciences AVXL Stock Holding History

Ensign Peak Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,560
Closed -$202K – 1825
2022
Q3 		$202K Hold
19,560
– – ﹤0.01% 1868
2022
Q2 		$196K Hold
19,560
– – ﹤0.01% 1797
2022
Q1 		$241K Hold
19,560
– – ﹤0.01% 1825
2021
Q4 		$339K Buy
+19,560
New +$372K ﹤0.01% 1771

Other funds holding AVXL

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Ensign Peak Advisors's AVXL Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Anavex Life Sciences (AVXL) in Q4 2022, closing a stake of 19,560 shares — an estimated $202K sold.

Ensign Peak Advisors first reported a position in AVXL in Q4 2021 and held it in 4 quarters. The position peaked at $339K in Q4 2021. 139 funds tracked by Wall St. Rank hold AVXL as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Anavex Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 19,560 Anavex Life Sciences shares in Q4 2022, an estimated $202K.
  • Ensign Peak Advisors first reported a position in Anavex Life Sciences in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Anavex Life Sciences position peaked at $339K in Q4 2021.
  • 139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.